NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, Forecast & News

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) released its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.04. The biopharmaceutical company had revenue of $2.59 million for the quarter, compared to analysts' expectations of $1.73 million. Corbus Pharmaceuticals had a negative net margin of 175.16% and a negative return on equity of 169.38%. View Corbus Pharmaceuticals' Earnings History.

Corbus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Corbus Pharmaceuticals.

6 Wall Street analysts have issued 12 month price objectives for Corbus Pharmaceuticals' shares. Their forecasts range from $18.00 to $38.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $26.50 in the next twelve months. This suggests a possible upside of 294.9% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.

News articles about CRBP stock have been trending extremely negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Corbus Pharmaceuticals earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Corbus Pharmaceuticals.

Some companies that are related to Corbus Pharmaceuticals include Insmed (INSM), Akcea Therapeutics (AKCA), Zymeworks (ZYME), Arvinas (ARVN), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Ligand Pharmaceuticals (LGND), Amneal Pharmaceuticals (AMRX), Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), Theravance Biopharma (TBPH), Innoviva (INVA), Esperion Therapeutics (ESPR), BELLUS Health (BLUSF) and Y-mAbs Therapeutics (YMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Exelixis (EXEL), Viveve Medical (VIVE), Canopy Growth (CGC), Cronos Group (CRON), Western Digital (WDC) and Cara Therapeutics (CARA).

Corbus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include AdvisorShares Investments LLC (0.59%), AE Wealth Management LLC (0.16%), Aries Wealth Management (0.04%), RFG Advisory LLC (0.02%), IFP Advisors Inc (0.01%) and Exane Derivatives (0.01%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.

CRBP stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives, AE Wealth Management LLC, RFG Advisory LLC and IFP Advisors Inc. View Insider Buying and Selling for Corbus Pharmaceuticals.

CRBP stock was purchased by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC and Aries Wealth Management. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CRBP stock can currently be purchased for approximately $6.71.

Corbus Pharmaceuticals has a market capitalization of $433.94 million and generates $4.82 million in revenue each year. The biopharmaceutical company earns $-55,670,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Corbus Pharmaceuticals employs 77 workers across the globe.View Additional Information About Corbus Pharmaceuticals.

The official website for Corbus Pharmaceuticals is http://www.corbuspharma.com/.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]